KRAS and non-small cell lung carcinoma: This review aims to provide a clinical update on potential therapies for advanced NSCLC with KRAS mutations other than the more common G12C, for which good results have already been achieved, particularly focusing on clinical trials, molecules and mechanisms currently under investigation.